NC
BIB icon

NewSquare Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

NewSquare Capital’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$260 – 627
2023
Q2 		$260 Hold
5
– – ﹤0.01% 743
2023
Q1 		$271 Hold
5
– – ﹤0.01% 771
2022
Q4 		$289 Buy
+5
New +$282 ﹤0.01% 704

Other funds holding BIB

CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

NewSquare Capital's BIB Position: Q3 2023 in Review

NewSquare Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2023, closing a stake of 5 shares — an estimated $260 sold.

NewSquare Capital first reported a position in BIB in Q4 2022 and held it in 3 quarters. The position peaked at $289 in Q4 2022. 21 funds tracked by Wall St. Rank hold BIB as of Q3 2023.

  • NewSquare Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 5 ProShares Ultra NASDAQ Biotechnology shares in Q3 2023, an estimated $260.
  • NewSquare Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $289 in Q4 2022.
  • 21 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.